These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 29153603)
1. Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy. Stokes WA; Binder DC; Jones BL; Oweida AJ; Liu AK; Rusthoven CG; Karam SD J Neuroimmunol; 2017 Dec; 313():118-122. PubMed ID: 29153603 [TBL] [Abstract][Full Text] [Related]
2. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes. Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685 [TBL] [Abstract][Full Text] [Related]
3. Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases. Moyers JT; Chong EG; Peng J; Tsai HHC; Sufficool D; Shavlik D; Nagaraj G Cancer Med; 2021 Feb; 10(4):1201-1211. PubMed ID: 33484100 [TBL] [Abstract][Full Text] [Related]
4. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases. Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. Amaral T; Tampouri I; Eigentler T; Keim U; Klumpp B; Heinrich V; Zips D; Paulsen F; Gepfner-Tuma I; Skardelly M; Tatagiba M; Tabatabai G; Garbe C; Forschner A Immunotherapy; 2019 Mar; 11(4):297-309. PubMed ID: 30606066 [TBL] [Abstract][Full Text] [Related]
6. Melanoma brain metastases: is it time to eliminate radiotherapy? White RJ; Abel S; Horne ZD; Lee J; Edington H; Greenberg L; Younes H; Hilton C; Wegner RE J Neurooncol; 2020 Aug; 149(1):27-33. PubMed ID: 32556863 [TBL] [Abstract][Full Text] [Related]
7. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases. Hall MD; McGee JL; McGee MC; Hall KA; Neils DM; Klopfenstein JD; Elwood PW J Neurosurg; 2014 Dec; 121 Suppl():84-90. PubMed ID: 25434941 [TBL] [Abstract][Full Text] [Related]
16. The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival. Vecchio S; Spagnolo F; Merlo DF; Signori A; Acquati M; Pronzato P; Queirolo P Melanoma Res; 2014 Feb; 24(1):61-7. PubMed ID: 24121190 [TBL] [Abstract][Full Text] [Related]
17. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Patel KR; Lawson DH; Kudchadkar RR; Carthon BC; Oliver DE; Okwan-Duodu D; Ahmed R; Khan MK Neuro Oncol; 2015 Oct; 17(10):1312-21. PubMed ID: 26014049 [TBL] [Abstract][Full Text] [Related]
18. Metastatic melanoma: prognostic factors and survival in patients with brain metastases. Frinton E; Tong D; Tan J; Read G; Kumar V; Kennedy S; Lim C; Board RE J Neurooncol; 2017 Dec; 135(3):507-512. PubMed ID: 28819707 [TBL] [Abstract][Full Text] [Related]